Novartis reported second-quarter 2026 net sales of $14.4 billion [1], beating analyst expectations for the period ending July 21, 2026 [4].
These results arrive as the pharmaceutical giant faces critical patent expiries on several key products. The company's ability to maintain growth during this transition is vital for investor confidence and long-term valuation.
CEO Vas Narasimhan said the company delivered net sales that rose three% year-over-year [3]. While some reports suggest sales reached $14.5 billion [3], the company's primary financial reporting indicates the $14.4 billion figure [1]. The firm also reported a core operating profit of $5.94 billion [2] for the second quarter.
Speaking in London during an interview with CNBC Television, Narasimhan addressed the upcoming "patent cliffs" that often threaten revenue for major drugmakers. He said, "We remain confident in our pipeline and see no change in our strategic plan."
Narasimhan also highlighted the performance of the company's cholesterol franchise. He said Leqvio continues to drive momentum, and that the company is unfazed by competition from oral PCSK9 treatments.
The financial results follow a period of strategic realignment for the company. The Q2 beat suggests that the current portfolio is offsetting the risks associated with older drugs losing their market exclusivity.
Narasimhan said the results justify the company's current trajectory and reinforced that the internal roadmap remains the primary guide for the firm's operations.
“"We remain confident in our pipeline and see no change in our strategic plan."”
The earnings beat demonstrates Novartis's ability to generate growth through new product launches like Leqvio, which helps mitigate the financial impact of patent expiries. By maintaining a steady core operating profit of $5.94 billion, the company is signaling to the market that its transition from legacy blockbusters to a new generation of specialty medicines is progressing as planned.
